Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
NCT Number: NCT02769299
The overall objective of this proposal is to determine the utility of sensitive imaging and biomarker measures in detecting subclinical cardiotoxicity across a spectrum of radiation doses to the heart. We will focus specifically on patients receiving photon or proton chest radiotherapy. Our broad working hypothesis is that RT induces early, subclinical CV injury, as evidenced by cardiomyocyte inflammation and necrosis, and worsening CV function.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Philadelphia, Pennsylvania, 19104, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
less than 1 Gy with protons to 4-8 Gy with photons
Time frame: 8 months
Abramson Cancer Center at Penn Medicine
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05708950
Adnexal Diseases, Breast Cancer
Santa Monica, California, United States
View Trial DetailsNCT07651020
Adnexal Diseases, Astrocytoma
Wuhan, Hubei, China
View Trial DetailsNCT00600496
Breast Cancer, Breast Diseases
Detroit, Michigan, United States
View Trial DetailsNCT06255041
Breast Cancer, Breast Diseases
Haifa, Israel
View Trial Details